CpG motifs as immune adjuvants - PubMed (original) (raw)
CpG motifs as immune adjuvants
D M Klinman et al. Vaccine. 1999 Jan.
Abstract
Bacterial DNA contains immunostimulatory motifs that trigger an innate immune response characterized by the production of predominantly Th1-type cytokines. These motifs consist of an unmethylated CpG dinucleotide flanked by two 5' purines and two 3' pyrimidines. We examined whether synthetic oligodeoxynucleotides (oligos) expressing these motifs would act as adjuvants to boost the immune response to DNA- and protein-based immunogens. In vivo experiments demonstrate that CpG-containing oligos augment antigen-specific serum antibody levels by up to tenfold, and IFNgamma production by up to sixfold. These effects were optimized by physically linking the CpG-containing motifs to the immunogen.
Similar articles
- Adjuvant activity of CpG oligodeoxynucleotides.
Klinman DM. Klinman DM. Int Rev Immunol. 2006 May-Aug;25(3-4):135-54. doi: 10.1080/08830180600743057. Int Rev Immunol. 2006. PMID: 16818369 Review. - Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.
Jones TR, Obaldia N 3rd, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, Davis HL, Krieg AM, Hoffman SL. Jones TR, et al. Vaccine. 1999 Aug 6;17(23-24):3065-71. doi: 10.1016/s0264-410x(99)00145-0. Vaccine. 1999. PMID: 10462241 - A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine.
Sugai T, Mori M, Nakazawa M, Ichino M, Naruto T, Kobayashi N, Kobayashi Y, Minami M, Yokota S. Sugai T, et al. Vaccine. 2005 Nov 16;23(46-47):5450-6. doi: 10.1016/j.vaccine.2004.09.041. Epub 2005 Jun 21. Vaccine. 2005. PMID: 16006019 - Contribution of CpG motifs to the immunogenicity of DNA vaccines.
Klinman DM, Yamshchikov G, Ishigatsubo Y. Klinman DM, et al. J Immunol. 1997 Apr 15;158(8):3635-9. J Immunol. 1997. PMID: 9103425 - Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
Wilson HL, Dar A, Napper SK, Marianela Lopez A, Babiuk LA, Mutwiri GK. Wilson HL, et al. Int Rev Immunol. 2006 May-Aug;25(3-4):183-213. doi: 10.1080/08830180600785868. Int Rev Immunol. 2006. PMID: 16818371 Review.
Cited by
- Novel adjuvant nano-vaccine induced immune response against Acinetobacter baumannii.
Piri-Gharaghie T, Doosti A, Mirzaei SA. Piri-Gharaghie T, et al. AMB Express. 2023 Mar 11;13(1):31. doi: 10.1186/s13568-023-01531-0. AMB Express. 2023. PMID: 36905472 Free PMC article. - Development of therapeutic antibodies for the treatment of diseases.
Wang Z, Wang G, Lu H, Li H, Tang M, Tong A. Wang Z, et al. Mol Biomed. 2022 Nov 22;3(1):35. doi: 10.1186/s43556-022-00100-4. Mol Biomed. 2022. PMID: 36418786 Free PMC article. Review. - Maximizing TLR9 Activation in Cancer Immunotherapy with Dual-Adjuvanted Spherical Nucleic Acids.
Chen P, Wang D, Wang Y, Zhang L, Wang Q, Liu L, Li J, Sun X, Ren M, Wang R, Fang Y, Zhao JJ, Zhang K. Chen P, et al. Nano Lett. 2022 May 25;22(10):4058-4066. doi: 10.1021/acs.nanolett.2c00723. Epub 2022 May 6. Nano Lett. 2022. PMID: 35522597 Free PMC article. - Applications of DNA-Functionalized Proteins.
Gong Z, Tang Y, Ma N, Cao W, Wang Y, Wang S, Tian Y. Gong Z, et al. Int J Mol Sci. 2021 Nov 29;22(23):12911. doi: 10.3390/ijms222312911. Int J Mol Sci. 2021. PMID: 34884714 Free PMC article. Review. - Functionalizing DNA nanostructures for therapeutic applications.
Henry SJW, Stephanopoulos N. Henry SJW, et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Nov;13(6):e1729. doi: 10.1002/wnan.1729. Epub 2021 May 19. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021. PMID: 34008347 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources